Relay Therapeutics (NASDAQ: RLAY) saw a 15% increase in its share price this week, following a bullish new analyst note from Guggenheim Securities’ Brad Canino. The analyst initiated coverage with a price target of $15 per share, pointing to the promising late-stage breast cancer trial for RLY-2608. Financially, Relay reported earnings of $677,000 in the second quarter, a significant improvement from the previous year. With positive developments in both drug development and financial performance, the company seems to be on a promising trajectory for the future.

Read more at Nasdaq: Why Relay Therapeutics Stock Rocketed Nearly 15% Higher This Week